2026-11-16T21:36:29.000Z · 17 hours ago Aytu BioPharma to be acquired by Rosemont Pharmaceuticals for $2.70 per share
Nov 16, 2026, 4:11 PM EST · 17 hours ago Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
Sep 22, 2026, 4:05 PM EDT · 7 weeks ago Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Sep 16, 2026, 4:30 PM EDT · 2 months ago Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
Jun 1, 2026, 4:15 PM EDT · 5 months ago Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
May 18, 2026, 4:05 PM EDT · 6 months ago Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 13, 2026, 4:05 PM EDT · 6 months ago Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
May 6, 2026, 4:05 PM EDT · 6 months ago Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
Feb 3, 2026, 4:05 PM EST · 9 months ago Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Jan 27, 2026, 4:05 PM EST · 9 months ago Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Jan 20, 2026, 4:05 PM EST · 10 months ago Aytu BioPharma Recaps Investor Day Held on January 20, 2026
2026-01-20T14:20:18.000Z · 10 months ago Aytu BioPharma announces nationwide commercial launch of EXXUA
Jan 13, 2026, 4:15 PM EST · 10 months ago Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Jan 12, 2026, 8:00 AM EST · 10 months ago Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
Dec 18, 2025, 9:00 AM EST · 11 months ago Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
2025-12-15T14:20:55.000Z · 11 months ago Aytu BioPharma announces commercial availability of EXXUA tablets
Dec 15, 2025, 9:00 AM EST · 11 months ago Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
Nov 24, 2025, 4:05 PM EST · 11 months ago Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Nov 13, 2025, 4:05 PM EST · 1 year ago Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Nov 5, 2025, 4:05 PM EST · 1 year ago Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
Oct 10, 2025, 9:00 AM EDT · 1 year ago Aytu BioPharma to Present at Upcoming October 2025 Conferences
Sep 24, 2025, 4:15 PM EDT · 1 year ago Aytu BioPharma to Present at Upcoming September 2025 Conferences
Sep 23, 2025, 4:05 PM EDT · 1 year ago Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
Sep 16, 2025, 4:05 PM EDT · 1 year ago Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
2025-06-25T12:30:52.000Z · 1 year ago Aytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs
Jun 25, 2025, 8:00 AM EDT · 1 year ago Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
Jun 23, 2025, 8:00 AM EDT · 1 year ago Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
Jun 9, 2025, 4:30 PM EDT · 1 year ago Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
Jun 6, 2025, 8:01 AM EDT · 1 year ago Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
Jun 6, 2025, 8:00 AM EDT · 1 year ago Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
May 14, 2025, 4:05 PM EDT · 1 year ago Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
May 7, 2025, 4:15 PM EDT · 1 year ago Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
Apr 21, 2025, 4:05 PM EDT · 1 year ago Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Feb 12, 2025, 4:03 PM EST · 1 year ago Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Feb 5, 2025, 5:50 PM EST · 1 year ago Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
Jan 6, 2025, 9:00 AM EST · 1 year ago Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Nov 22, 2024, 9:00 AM EST · 1 year ago Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
Nov 13, 2024, 4:05 PM EST · 2 years ago Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
Nov 6, 2024, 5:20 PM EST · 2 years ago Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
Oct 14, 2024, 4:15 PM EDT · 2 years ago Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
Oct 1, 2024, 8:00 AM EDT · 2 years ago Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
Sep 26, 2024, 4:15 PM EDT · 2 years ago Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
Sep 19, 2024, 5:30 PM EDT · 2 years ago Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
Aug 8, 2024, 5:20 PM EDT · 2 years ago Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
Aug 6, 2024, 8:00 AM EDT · 2 years ago Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Jun 18, 2024, 8:00 AM EDT · 2 years ago Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
May 15, 2024, 4:05 PM EDT · 2 years ago Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
May 8, 2024, 4:15 PM EDT · 2 years ago Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Apr 3, 2024, 9:00 AM EDT · 2 years ago Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Feb 14, 2024, 4:05 PM EST · 2 years ago Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter